
Bayer's Monsanto loses appeal of $611M Roundup verdict in Missouri
May 28 (Reuters) - A Missouri appellate court has upheld a $611 million verdict awarded to three people who sued Bayer alleging that its Roundup weedkiller caused their cancer, a ruling the company says it will further appeal.
The decision from the Missouri Court of Appeals' Western District on Tuesday rejected Bayer unit Monsanto's argument that the lower court impermissibly allowed testimony at the 2023 trial about a ruling from the San Francisco-based 9th U.S. Circuit Court of Appeals in a separate case about the cancer risks of glyphosate, the pesticide in Roundup.
Bayer is wrong in arguing that judicial opinions are categorically inadmissible at a jury trial, the court said. The court upheld the $611 million in compensatory and punitive damages awarded to Daniel Anderson, Jimmy Draeger and Valorie Gunther after their lawsuits were consolidated and tried before a jury.
Bayer has faced thousands of lawsuits over whether Roundup causes cancer since it bought Monsanto for $63 billion in 2018. It agreed to settle much of that litigation for $10.9 billion in 2020, but failed to resolve future cases. About 67,000 remain, in both federal and state court.
Though Bayer has prevailed in many of the Roundup trials, plaintiffs have won more than $4 billion of verdicts. Bayer has been pursuing appeals to reduce the verdict amounts while petitioning the U.S. Supreme Court to resolve a broader swath of the cases.
One of Bayer's defenses in the litigation has been that the U.S. Environmental Protection Agency has determined that glyphosate doesn't pose a risk to human health.
To counter that argument, the plaintiffs in Tuesday's case had told the jury that the 9th Circuit in 2022 found the EPA's determination that glyphosate was not likely to cause cancer was not supported by the evidence and directed the agency to reexamine it.
In a statement, a representative for Monsanto said the company will be seeking further review of the decision to allow the opinion to be presented to jurors.
'In the majority of other cases which went to trial in Missouri, judges properly excluded inadmissible evidence, leading to positive outcomes for the Company,' the statement said.
An attorney for the plaintiffs did not respond to requests for comment.
The plaintiffs filed their lawsuits in 2022, claiming they each had been diagnosed with non-Hodgkin's lymphoma after years of using Roundup to control weeds.
A Cole County, Missouri, jury found Monsanto liable for negligence, selling a defective product and failing to warn about Roundup's risks. They awarded $61.1 million of compensatory damages and $1.5 billion of punitive damages.
In March 2024, the trial judge had let the $61.1 million component stand, but reduced punitive damages to nine times that amount, or $549.9 million. The U.S. Supreme Court has said that punitive damages should generally not be more than nine times compensatory damages.
In Tuesday's decision, the appellate court also rejected another of the company's key arguments, that federal law blocks any state law claim that the company failed to warn consumers about the risks. The court agreed with another Missouri appellate district that found Monsanto had not shown an irreconcilable conflict between the federal and state laws.
Thousands of other Roundup cases are pending in Missouri. Another trial over Roundup is underway in St. Louis. It is expected to last through mid-June.
The case is Anderson v. Monsanto Co., Missouri Court of Appeals, Western District, No. WD87059.
For Monsanto: Barbara Smith Tyson of Bryan Cave Leighton Paisner
For the plaintiffs: Edward Robertson of Bartimus Frickleton Robertson Rader
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
32 minutes ago
- Daily Mail
Magda Szubanski gets emotional as she thanks family, friends and fans for their support after revealing her stage four cancer diagnosis: 'The wind beneath my wings'
Magda Szubanski has expressed immense gratitude in the wake of her devastating stage four cancer diagnosis. The beloved Aussie comedian, 64, who revealed she is battling Mantle Cell Lymphoma last week, took to Instagram to thank her family, friends and fans for the outpouring of support. Speaking in a video posted on Sunday, Magda said she had been 'overwhelmed' by the response to her announcement. 'I just wanted to say a massive thank you for all the love and support,' she said in the clip. 'It's just been so moving and, really, youse are the wind beneath my wings. Thank you very much, love you all. Sorry I can't reply this. From A-list scandals and red carpet mishaps to exclusive pictures and viral moments, subscribe to the DailyMail's new showbiz newsletter to stay in the loop. 'It's pretty overwhelming, but I just feel so loved.' Last week, Magda shocked her followers when she revealed she was battling a rare and fast-moving blood cancer. She appeared on camera with a shaved head after beginning her treatment to fight the disease. 'Hello my lovelies. So, the head is shaved in anticipation of it all falling out in a couple of weeks because I have just been diagnosed with a very rare, very aggressive, very serious lymphoma,' she began. 'It is one of the nasty ones, unfortunately. But the good thing is I'm surrounded by beautiful friends and family and an incredible medical support team. 'Honestly, we have the best in the world here in Australia, particularly in Melbourne, so I feel very fortunate. 'It's pretty confronting. It is a full on. But new treatments keep coming down the pipeline all the time.' Magda said she has started a treatment called the Nordic protocol, which treats Mantle Cell Lymphoma by shrinking the tumours with a combination of drugs administered in five phases. It's known as the Nordic regimen based upon its clinical trial sites in Denmark and Norway. The actress explained she will be 'lying very low' due to her weak immune system. 'I won't sugar-coat it: it's rough. But I'm hopeful. I'm being lovingly cared for by friends and family, my medical team is brilliant, and I've never felt more held by the people around me,' she said. 'Please keep a distance though because I will be very immunocompromised. So I can't hug no more. 'Don't hug me, kiss me, or breathe anywhere near me! Wave enthusiastically from a safe distance and know I love you madly.' The Kath & Kim star said the cancer was discovered during a routine breast screening. 'This is an obscure cancer and was only discovered incidentally via a breast screen where they found my lymph nodes were up,' she explained. 'TBH, I've been feeling pretty rats**t for ages. So I asked for extra bloods and - voila! So the take away is - get tested and listen to your body! 'For now, just know I'm in good hands, good spirits - but I reserve my human right to be a cranky old moll. Love you all, Mags.'


BBC News
39 minutes ago
- BBC News
Kerr gains revenge at latest Grand Slam Track meet
Great Britain's Josh Kerr avenged his Olympic 1500m defeat by Cole Hocker in a thrilling battle in Sunday's Grand Slam Track surged past Kerr, 27, to claim a shock victory and Olympic gold in Paris last it was Kerr's turn to produce a decisive finish in Philadelphia, storming past the American in the final few metres to win by seven-hundredths of a claimed victory in a season's best time of three minutes 34.44 a fifth-placed finish in the 800m on Saturday, Kerr missed out on the top prize of $100,000 (£74,000) for the short distance group by just one point to Canada's Marco Arop, who won the the women's 100m, US sprinter Melissa Jefferson-Wooden clocked a world-leading time as she stormed to an emphatic Olympic bronze medallist, 24, claimed victory in a personal best 10.73secs, making her the 10th fastest woman to run the distance, tied with France's Christine Arron."It means everything, I've been working so hard for this," said Jefferson-Wooden, who also won the 200m on Saturday. "It's just all coming together."Compatriot Tamari Davis placed second in 11.03secs, with Great Britain's Dina Asher-Smith fifth in 11.16secs. GB's Matthew Hudson-Smith clinched the top prize for the men's long sprints group for the second time in three winning the 400m in 44.51 on Saturday, the 30-year-old's fifth-place finish in the 200m was enough to claim another Grand Slam title, having secured the first in Kingston, Slam Track is a new competition created by Michael Johnson which aims to bring the world's fastest athletes together to compete for lucrative events were scheduled for the opening series and the final meet will be in Los Angeles from 27-29 June.


Reuters
41 minutes ago
- Reuters
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
June 2 (Reuters) - Pharma firm Indivior (INDV.L), opens new tab said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. The company, known for its opioid addiction treatment, joins a growing number of companies delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets. Shares of Indivior, which floated in London in late 2014, have dropped more than 60% from record highs hit in June 2018. The company said over 80% of its revenue now comes from the U.S., with the Nasdaq (NDAQ.O), opens new tab accounting for about 75% of recent trading volumes. The delisting aims to streamline operations and reflect the company's strategic focus on the U.S. market, it said. Indivior moved its primary listing to the United States last year. The decision to delist from London comes just months after Indivior overhauled its management. Earlier this year, it appointed David Wheadon as chair and Joe Ciaffoni as CEO.